The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Tumor Cells, Cultured

This is a "connection" page, showing publications Mary Eileen Dolan has written about Tumor Cells, Cultured.
Connection Strength

0.898
  1. Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1991 Sep; 12(9):1679-83.
    View in: PubMed
    Score: 0.089
  2. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5368-72.
    View in: PubMed
    Score: 0.082
  3. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
    View in: PubMed
    Score: 0.055
  4. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther. 2005 Jan; 312(1):206-13.
    View in: PubMed
    Score: 0.054
  5. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther. 2003 Jul; 2(7):633-40.
    View in: PubMed
    Score: 0.050
  6. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.047
  7. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res. 2002 Aug; 8(8):2696-700.
    View in: PubMed
    Score: 0.047
  8. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs. 1998 Jun; 9(5):437-48.
    View in: PubMed
    Score: 0.035
  9. O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases. Biochem Pharmacol. 1998 May 15; 55(10):1701-9.
    View in: PubMed
    Score: 0.035
  10. Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol. 1998; 41(6):505-12.
    View in: PubMed
    Score: 0.034
  11. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26; 50(9):1385-9.
    View in: PubMed
    Score: 0.030
  12. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol. 1995 Oct 12; 50(8):1141-8.
    View in: PubMed
    Score: 0.029
  13. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 1994 Sep 01; 54(17):4698-702.
    View in: PubMed
    Score: 0.027
  14. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(1):59-63.
    View in: PubMed
    Score: 0.024
  15. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993; 32(3):221-5.
    View in: PubMed
    Score: 0.024
  16. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 01; 52(5):1171-5.
    View in: PubMed
    Score: 0.023
  17. Production of antibodies to peptide sequences present in human O6-alkylguanine-DNA alkyltransferase and their use to detect this protein in cell extracts. Carcinogenesis. 1991 Sep; 12(9):1671-7.
    View in: PubMed
    Score: 0.022
  18. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72.
    View in: PubMed
    Score: 0.022
  19. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990; 2(11):371-7.
    View in: PubMed
    Score: 0.020
  20. Intracellular activation of cytotoxic agents: kinetic models for methylnitrosoureas and N-methyl-N'-nitro-N-nitrosoguanidine in cell culture. Chem Res Toxicol. 1989 May-Jun; 2(3):157-61.
    View in: PubMed
    Score: 0.019
  21. Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate. Cancer Res. 1988 Jul 01; 48(13):3603-6.
    View in: PubMed
    Score: 0.018
  22. Investigation of the specificity of O6-alkylguanine-DNA-alkyltransferase. Chem Biol Interact. 1988; 65(3):275-81.
    View in: PubMed
    Score: 0.017
  23. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005 Sep; 4(9):1364-8.
    View in: PubMed
    Score: 0.015
  24. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000 Nov 15; 60(22):6307-10.
    View in: PubMed
    Score: 0.010
  25. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000 Oct; 6(10):4154-7.
    View in: PubMed
    Score: 0.010
  26. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
    View in: PubMed
    Score: 0.010
  27. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother Pharmacol. 1999; 43(1):80-5.
    View in: PubMed
    Score: 0.009
  28. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994 Nov 29; 48(11):2127-34.
    View in: PubMed
    Score: 0.007
  29. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15; 54(16):4371-5.
    View in: PubMed
    Score: 0.007
  30. Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1994 Feb 04; 37(3):342-7.
    View in: PubMed
    Score: 0.007
  31. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15; 53(18):4281-6.
    View in: PubMed
    Score: 0.006
  32. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32(6):477-81.
    View in: PubMed
    Score: 0.006
  33. Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1992 Nov 13; 35(23):4486-91.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.